Day One Biopharmaceuticals (DAWN)

Why Revenue Could Explode

1. 01FDA regulatory decisions on tovorafenib for pediatric low-grade glioma (PDUFA-type dates, advisory committee outcomes)
2. 02Clinical trial data readouts for expansion cohorts (adult glioma, other BRAF-altered solid tumors, combination studies)
3. 03Commercial launch metrics post-approval: patient starts, market penetration in ~1,000-1,500 annual US pLGG diagnoses, pricing/reimbursement decisions
4. 04Partnership announcements or ex-US licensing deals that validate platform and provide non-dilutive funding
5. 05Cash runway updates and financing events (equity raises, debt facilities) given -$100M annual burn rate

DAWN Chart

My Notes

• growth - Pure binary clinical/regulatory catalyst play attracting biotech specialists, event-driven funds…
• Rising rates negatively impact valuation through higher discount rates applied to distant cash flows (tovorafenib peak sales likely…
• Watch on earnings: FDA action dates and regulatory milestone achievements for tovorafenib NDA in pediatric low-grade glioma, Clinical trial data releases: objective response rates, progression-free survival, safety profiles in expansion studies, Quarterly cash burn rate and runway calculations relative to anticipated approval timelines.